BEACITA * 84CPS 60MG
Alli is indicated for weight loss in overweight adults (body mass index, BMI, ≥ 28 kg / m²) and should be taken in conjunction with a moderately low calorie, reduced fat diet.
Dosage and method of use
Dosage Adults The recommended dosage for treatment is one 60 mg capsule to be taken three times a day. No more than three 60 mg capsules should be taken in any 24 hours. Diet and exercise are important components of a weight loss program. It is recommended that a diet and exercise program be started before starting treatment with alli. During treatment with orlistat, the patient should follow a nutritionally balanced and moderately low-calorie diet, which contains approximately 30% of calories from fat (e.g. in a 2000 kcal per day diet, this is equivalent to a quantitySpecial populations Pediatric populationAlli should not be used in children and adolescents below 18 years of age due to insufficient data on safety and efficacy.Elderly (> 65 years)Only limited data are available on the use of orlistat in the elderly. However, as orlistat is only minimally absorbed, no dose adjustment is required in the elderly.Hepatic and renal impairmentThe effects of orlistat in subjects with hepatic and / or renal impairment have not been studied (see section 4.4). However, as orlistat is only minimally absorbed, no dose adjustment is required in subjects with hepatic and / or renal impairment. Pediatric population The safety and efficacy of alli in children below 18 years of age have not yet been established. No data are available.Method of administrationThe capsule should be taken with water immediately before, during or within one hour after the main meals. If a meal is skipped or contains no fat, the orlistat dose should be omitted.
- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1; - Concomitant treatment with cyclosporine (see section 4.5); - Chronic malabsorption syndrome; - Cholestasis; - Pregnancy (see section 4.6); - Breastfeeding (see section 4.6); - Concomitant treatment with warfarin or other oral anticoagulants (see sections 4.5 and 4.8).
Summary of the safety profileAdverse reactions to orlistat are predominantly affecting the gastrointestinal tract and are related to the pharmacological effect of the drug on inhibiting the absorption of ingested fats. Gastrointestinal adverse reactions identified in clinical studies with orlistat 60 mg lasting 18 months to 2 years were generally mild and transient. They generally occurred early in treatment (within 3 months) and most patients experienced only one episode. Consumption of a low fat diet tends to decrease the likelihood of developing gastrointestinal adverse reactions (see section 4.4).Tabular list of adverse reactionsAdverse reactions are listed below by system organ class and frequency. Frequencies are defined as follows: very common (≥ 1/10), common (≥ 1/100,
| System and organ classification
| Adverse reaction
| Infections and infestations
| Disorders of the blood and lymphatic system
|Decreased prothrombin and increased INR (see sections 4.3 and 4.5).
| Disorders of the immune system
|Hypersensitivity reactions, including anaphylaxis, bronchospasm, angioedema, pruritus, erythema and urticaria.
| Psychiatric disorders
| Gastrointestinal disorders
|Oily leaks, Flatulence with stool emission, Urgent defecation, Fatty oily stools, Oily evacuation, Flatulence, Soft stools;
|Abdominal pain, Faecal incontinence, Liquid stools, Increased defecation;
|Diverticulitis, Pancreatitis, Mild rectal bleeding (see section 4.4).
| Hepatobiliary disorders
|Potentially serious hepatitis (some fatal cases or cases requiring liver transplantation have been reported), cholelithiasis, increased transaminases and alkaline phosphatase.
| Skin and subcutaneous tissue disorders
| Renal and urinary disorders
|Oxalate nephropathy which can lead to kidney failure.
¹ It is plausible that treatment with orlistat may induce anticipatory anxiety or secondary to gastrointestinal adverse reactions.Reporting of suspected adverse reactionsReporting of suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit / risk ratio of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.aifa.gov.it/content/segnalazioni-reazioni-avverse.
Gastrointestinal symptomsPatients should be advised to adhere to received dietary recommendations (see section 4.2). The possibility of developing gastrointestinal symptoms (see section 4.8) may be increased if orlistat is taken with a single meal or a high-fat diet.Fat-soluble vitaminsTreatment with orlistat may impair the absorption of fat-soluble vitamins (A, D, E and K) (see section 4.5). For this reason, a multivitamin supplement should be taken before bedtime.Antidiabetic medicinesSince weight loss may be associated with improved metabolic control of diabetes, patients taking a diabetes medicine should consult their doctor before starting treatment with Alli if it becomes necessary to adjust the dose of the antidiabetic medicine.Medicines for hypertension and hypercholesterolemiaWeight loss can be associated with an improvement in blood pressure and cholesterol levels. Patients taking a medicine for hypertension or hypercholesterolemia should consult their doctor or pharmacist during treatment with Alli if it becomes necessary to adjust the dose of these medicines.AmiodaronePatients taking amiodarone should consult their doctor or pharmacist before starting treatment with alli (see section 4.5).Rectal bleedingThere have been reports of rectal bleeding in patients taking orlistat. Should this occur, the patient should consult a physician.Oral contraceptivesThe use of an additional contraceptive method is recommended to prevent the possible failure of oral contraceptives which could occur in case of severe diarrhea (see section 4.5).NephropathyPatients with kidney problems should consult a physician before starting treatment with alli, as the use of orlistat may be associated with hyperoxaluria and oxalate nephropathy which sometimes leads to renal failure. This risk is increased in patients with latent chronic kidney disease and / or volume depletion.LevothyroxineHypothyroidism and / or reduced control of hypothyroidism may occur when orlistat and levothyroxine are taken simultaneously (see section 4.5). Patients taking levothyroxine should consult their doctor before starting treatment with alli as it may be necessary to take orlistat and levothyroxine at different times and to adjust the levothyroxine dose.Antiepileptic medicinesPatients taking an anti-epileptic drug should consult their physician before starting treatment with ale, as they should be monitored for any changes in the frequency and intensity of seizures. Should this occur, consideration should be given to administering orlistat and anti-epileptic drugs at different times (see section 4.5).Antiretrovirals for HIVPatients should consult a physician before taking orlistat concomitantly with antiretroviral medicinal products. Orlistat has the potential to reduce the absorption of HIV antiretroviral medicinal products and may adversely affect the efficacy of HIV antiretroviral medicinal products (see section 4.5).Information on excipientsBeacita Aurobindo 60 mg hard capsules contain less than 1 mmol (23 mg) sodium per capsule, i.e. essentially 'sodium-free'.
Pregnancy and breastfeeding
Women of childbearing potential / contraception in men and womenThe use of an additional contraceptive method is recommended to prevent possible ineffectiveness of oral contraception in case of severe diarrhea (see sections 4.4 and 4.5).PregnancyNo clinical data on exposure during pregnancy are available for orlistat. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal / fetal development, parturition or postnatal development (see section 5.3). Beacita is contraindicated in pregnancy (see section 4.3).BreastfeedingSince it is not known whether orlistat is excreted in human milk, alli is contraindicated during lactation (see section 4.3).FertilityAnimal studies do not indicate harmful effects on fertility.
Expiration and retention
Do not store above 25 ° C. Store in the original package in order to protect the medicine from light and moisture.
Interactions with other drugs
CyclosporineA decrease in plasma levels of cyclosporine was observed in a drug interaction study and was also reported in many cases of concomitant administration with orlistat. This could lead to a decrease in the immunosuppressive efficacy of cyclosporine. Concomitant use of alli and cyclosporine is therefore contraindicated (see section 4.3).Oral anticoagulantsAdministration of warfarin or other oral anticoagulants concomitantly with orlistat may affect the international normalized ratio values (International Normalized RatioINR) (see section 4.8). Concomitant use of alli and warfarin or other oral anticoagulants is therefore contraindicated (see section 4.3).Oral contraceptivesThe absence of an interaction between oral contraceptives and orlistat has been demonstrated in specific drug interaction studies. However, orlistat may indirectly reduce the availability of oral contraceptives and lead, in some individual cases, to unwanted pregnancy. An additional contraceptive method is recommended in case of severe diarrhea (see section 4.4).LevothyroxineHypothyroidism and / or reduced control of hypothyroidism may occur when orlistat and levothyroxine are taken simultaneously (see section 4.4). These effects may be due to a reduced absorption of iodine and / or levothyroxine salts.Anti-epileptic drugsCases of seizures have been reported in patients treated concomitantly with orlistat and anti-epileptic drugs, such as e.g. valproate, lamotrigine; for such cases a causal relationship due to an interaction cannot be excluded. Orlistat can decrease the absorption of anti-epileptic drugs, leading to seizures.Antiretroviral medicinesBased on literature data and post-marketing experience, orlistat has the potential to reduce the absorption of HIV antiretroviral medicinal products and may adversely affect the efficacy of HIV antiretroviral medicinal products (see section 4.4).Fat-soluble vitaminsOrlistat therapy has the potential to reduce the absorption of fat-soluble vitamins (A, D, E and K). In clinical studies, levels of vitamins A, D, E and K, and beta-carotene remained within the normal range in a large majority of subjects receiving orlistat therapy for up to 4 years. However, patients should be advised to take a multivitamin supplement at bedtime to help ensure adequate vitamin intake (see section 4.4).AcarboseIn the absence of pharmacokinetic interaction studies, Beacita is not recommended in patients treated with acarbose.AmiodaroneA decrease in plasma levels of amiodarone, given as a single dose, was observed in a limited number of healthy volunteers treated concomitantly with orlistat. The clinical relevance of this effect in patients receiving amiodarone is still unknown. Patients taking amiodarone should consult their doctor before starting treatment with alli. Amiodarone dose adjustment may be required during treatment with alli.Antidepressants, antipsychotics (including lithium) and benzodiazepinesA few cases of reduced efficacy of antidepressants, antipsychotics (including lithium) and benzodiazepines have been reported in conjunction with initiation of orlistat in previously well-controlled patients. Therefore, orlistat treatment should be initiated after careful consideration of the possible impact in these patients.
Single doses of 800 mg of orlistat and multiple doses of up to 400 mg three times daily for 15 days in normal weight and obese subjects were studied with no significant clinical evidence. In addition, doses of 240 mg three times a day were administered to obese patients for 6 months. The majority of post-marketing orlistat overdose cases reported no adverse reactions or reported adverse reactions similar to those reported with the recommended dose of orlistat. In the event of an overdose, medical attention should be sought. Should a significant overdose of orlistat occur, it is recommended that the patient be observed for 24 hours. Based on clinical and animal studies, all systemic effects attributable to orlistat's lipase inhibiting properties are expected to be rapidly reversible.
Each hard capsule contains 60 mg of orlistat. For the full list of excipients, see section 6.1.
Capsule contents: Microcrystalline cellulose PH112, sodium starch glycolate (type A), hydrophobic colloidal silica, sodium lauryl sulfate.Capsule shell: Gelatin, indigo carmine (E132), titanium dioxide (E171).